IRIS

Chloral hydrate

CASRN 302-17-0

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (39 pp, 220 K) last updated: 09/15/2000

System RfD (mg/kg-day) Basis PoD Composite UF Confidence
Nervous, Gastrointestinal 1 x 10-1 CNS depression and GI irritation in humans LOAEL : 1.07 x 101
mg/kg-day
100 High

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (39 pp, 220 K) last updated: 09/15/2000
Not assessed under the IRIS Program.

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (39 pp, 220 K) last updated: 09/15/2000

WOE Characterization Framework for WOE Characterization
C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Carcinogenic potential cannot be determined (Oral route) Proposed Guidelines for Carcinogen Risk Assessment (US EPA, 1996)
Basis:
  • Under the 1986 cancer guidelines (U.S. EPA, 1986), chloral hydrate is assigned to Group C, possible human carcinogen. Under the 1996 proposed guidelines for carcinogen risk assessment (U.S. EPA, 1996), chloral hydrate shows suggestive evidence of human carcinogenicity by the oral route of exposure. There are no carcinogenicity data from humans.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (39 pp, 220 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (39 pp, 220 K)

Not assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.